Eli Lilly and Company has announced that its Phase III study of Cialis (tadalafil) co-administered with finasteride, has met its primary endpoint in men with lower urinary tract symptoms of benign prostatic hyperplasia (LUTS/BPH) and enlarged prostate.
Cialis 5mg once-daily, co-administered with finasteride, considerably improved scores on the International Prostate Symptom Score (IPSS), compared to placebo / finasteride at four weeks, 12 weeks and 26 weeks.
Go deeper with GlobalData
Erectile function scores, a secondary endpoint, were improved in men who had both LUTS / BPH and erectile dysfunction (ED) at baseline by Cialis / finasteride, compared to placebo / finasteride.
The University of Texas Southwestern Medical Center Department of Urology chairman Dr Claus Roehrborn said; “Symptomatic improvement with 5-ARI therapy (finasteride) is observed after six to twelve months of treatment; therefore, the study aimed to understand if men with prostatic enlargement experience earlier improvement of BPH symptoms when tadalafil is co-administered with a 5-ARI therapy.”
A total of 696 men aged 45 years and older, with an IPSS of minimum 13, a urine flow rate (Qmax) of 4mm per second (ml/sec) to 15ml/sec and a prostate volume at least 30ml, were assessed for 26 weeks in the double-blind study.
The Treatment Satisfaction Scale-Benign Prostatic Hyperplasia (TSS-BPH) improved with Cialis / finasteride, compared to placebo / finasteride at 26 weeks, driven by satisfaction with efficacy, with no significant difference for dosing or side effects.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCialis, a phosphodiesterase type 5 inhibitor, was approved by the US Food and Drug Administration (FDA) for the signs and symptoms of BPH and both ED and the signs and symptoms of BPH (ED+BPH).
Finasteride, a type II 5alpha-reductase inhibitor (5-ARI), is cleared by the FDA for BPH in men with an enlarged prostate.
Image: Eli Lilly’s Phase III study is the first to report on co-administration of Cialis and finasteride in men with LUTS/BPH. Photo: Courtesy of Guanaco152003.
